Sensei Biotherapeutics (NASDAQ:SNSE) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Sensei Biotherapeutics (NASDAQ:SNSE) from a hold rating to a sell rating in a report published on Saturday.

Other equities analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Friday, April 24th. Leerink Partners started coverage on shares of Sensei Biotherapeutics in a report on Monday, April 20th. They issued an “outperform” rating and a $50.00 target price on the stock. Finally, Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $40.00.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ:SNSE opened at $20.43 on Friday. The firm has a market cap of $27.38 million, a PE ratio of -0.14 and a beta of -0.18. The firm’s fifty day moving average is $28.89 and its 200-day moving average is $17.87. Sensei Biotherapeutics has a 52 week low of $5.25 and a 52 week high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). Sell-side analysts forecast that Sensei Biotherapeutics will post -2.77 EPS for the current year.

Insider Transactions at Sensei Biotherapeutics

In other news, major shareholder Millennium Management Llc bought 15,321 shares of the company’s stock in a transaction that occurred on Friday, March 27th. The shares were acquired at an average price of $26.61 per share, for a total transaction of $407,691.81. Following the completion of the acquisition, the insider directly owned 142,360 shares in the company, valued at approximately $3,788,199.60. This represents a 12.06% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders have acquired 46,980 shares of company stock valued at $1,341,669 and have sold 23,067 shares valued at $704,439. 23.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 178.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 32,041 shares of the company’s stock after purchasing an additional 20,525 shares during the period. Renaissance Technologies LLC owned approximately 2.39% of Sensei Biotherapeutics worth $1,010,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics News Roundup

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.